A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

Objective To compare the uterine effects of 60 mg of raloxifene with a continuous combined hormone replacement therapy, a preparation of 2 mg 17β‐oestradiol (E2) and 1 mg norethisterone acetate for a duration of 12 months.

[1]  Kishore Shetty,et al.  Hormone replacement therapy , 2002, BMJ : British Medical Journal.

[2]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[3]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[4]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[5]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[6]  M. Larkin.  Ups and downs for HRT and heart disease , 2000, The Lancet.

[7]  W. Scheele,et al.  Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. , 2000, American journal of obstetrics and gynecology.

[8]  L. Plouffe,et al.  Uterine Effects of 3‐Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60 , 2000, Obstetrics and gynecology.

[9]  B. Walsh,et al.  A 12‐Month Comparative Study of Raloxifene, Estrogen, and Placebo on the Postmenopausal Endometrium , 2000, Obstetrics and gynecology.

[10]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[11]  V. Beral,et al.  Hormone Replacement Therapy: Patient Education Crucial , 1999, The Lancet.

[12]  I Persson,et al.  Risk of endometrial cancer following estrogen replacement with and without progestins. , 1999, Journal of the National Cancer Institute.

[13]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[14]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[15]  E. Barrett-Connor,et al.  Hormone replacement therapy , 1998, BMJ.

[16]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[17]  W. Huster,et al.  Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. , 1997, American journal of obstetrics and gynecology.

[18]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[19]  R. Mazess,et al.  Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. , 1994, Archives of internal medicine.

[20]  P. Neven,et al.  Guidelines for Monitoring Patients Taking Tamoxifen Treatment , 2000, Drug safety.

[21]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[22]  B. Mitlak,et al.  Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. , 1999, Menopause.

[23]  H. Judd,et al.  Bleeding Patterns over 3 Years in Postmenopausal Women Taking Placebo or Four Different Combinations of Estrogen and Progestins: The Postmenopausal Estrogen/Progestins Intervention (PEPI) Trial.: 26. , 1999 .

[24]  W. Holzgreve,et al.  Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. , 1999, Menopause.